Exicure, Inc. (NASDAQ:XCUR) Short Interest Down 78.8% in July

Exicure, Inc. (NASDAQ:XCUR) saw a large drop in short interest in July. As of July 31st, there was short interest totaling 107,470 shares, a drop of 78.8% from the July 15th total of 506,729 shares. Currently, 3.6% of the shares of the company are sold short. Based on an average daily volume of 138,757 shares, the short-interest ratio is currently 0.8 days.

Exicure Price Performance

Exicure stock traded up $0.01 during trading hours on Thursday, hitting $1.31. 50,639 shares of the stock traded hands, compared to its average volume of 103,315. The firm’s 50 day moving average price is $1.99 and its 200-day moving average price is $3.16. The stock has a market capitalization of $8.34 million, a price-to-earnings ratio of -0.85 and a beta of 3.65. Exicure has a 1 year low of $1.18 and a 1 year high of $9.48.

Exicure (NASDAQ:XCUR) last announced its quarterly earnings data on Friday, May 29th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($18.60) by $18.31.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut shares of Exicure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

About Exicure

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.